Free Trial

Mineralys Therapeutics (MLYS) Competitors

Mineralys Therapeutics logo
$41.99 -0.17 (-0.40%)
As of 10:22 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

MLYS vs. VRNA, RVMD, MRUS, RNA, GRFS, CYTK, RYTM, ABVX, CRSP, and NUVL

Should you be buying Mineralys Therapeutics stock or one of its competitors? The main competitors of Mineralys Therapeutics include Verona Pharma PLC American Depositary Share (VRNA), Revolution Medicines (RVMD), Merus (MRUS), Avidity Biosciences (RNA), Grifols (GRFS), Cytokinetics (CYTK), Rhythm Pharmaceuticals (RYTM), Abivax (ABVX), CRISPR Therapeutics (CRSP), and Nuvalent (NUVL). These companies are all part of the "pharmaceutical products" industry.

Mineralys Therapeutics vs. Its Competitors

Verona Pharma PLC American Depositary Share (NASDAQ:VRNA) and Mineralys Therapeutics (NASDAQ:MLYS) are both mid-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, dividends, risk, institutional ownership, valuation, analyst recommendations, earnings and media sentiment.

Verona Pharma PLC American Depositary Share has a beta of 0.05, meaning that its stock price is 95% less volatile than the S&P 500. Comparatively, Mineralys Therapeutics has a beta of 0.4, meaning that its stock price is 60% less volatile than the S&P 500.

Verona Pharma PLC American Depositary Share has higher revenue and earnings than Mineralys Therapeutics. Verona Pharma PLC American Depositary Share is trading at a lower price-to-earnings ratio than Mineralys Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Verona Pharma PLC American Depositary Share$42.28M217.94-$173.42M-$0.99-107.99
Mineralys TherapeuticsN/AN/A-$177.81M-$3.56-11.80

85.9% of Verona Pharma PLC American Depositary Share shares are held by institutional investors. Comparatively, 84.5% of Mineralys Therapeutics shares are held by institutional investors. 4.8% of Verona Pharma PLC American Depositary Share shares are held by insiders. Comparatively, 25.6% of Mineralys Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

In the previous week, Verona Pharma PLC American Depositary Share had 8 more articles in the media than Mineralys Therapeutics. MarketBeat recorded 12 mentions for Verona Pharma PLC American Depositary Share and 4 mentions for Mineralys Therapeutics. Verona Pharma PLC American Depositary Share's average media sentiment score of 1.10 beat Mineralys Therapeutics' score of 0.50 indicating that Verona Pharma PLC American Depositary Share is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Verona Pharma PLC American Depositary Share
7 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Mineralys Therapeutics
0 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Verona Pharma PLC American Depositary Share presently has a consensus price target of $109.00, suggesting a potential upside of 1.95%. Mineralys Therapeutics has a consensus price target of $43.50, suggesting a potential upside of 3.59%. Given Mineralys Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Mineralys Therapeutics is more favorable than Verona Pharma PLC American Depositary Share.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Verona Pharma PLC American Depositary Share
1 Sell rating(s)
12 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.07
Mineralys Therapeutics
1 Sell rating(s)
1 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
2.57

Mineralys Therapeutics has a net margin of 0.00% compared to Verona Pharma PLC American Depositary Share's net margin of -36.62%. Verona Pharma PLC American Depositary Share's return on equity of -21.12% beat Mineralys Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Verona Pharma PLC American Depositary Share-36.62% -21.12% -9.07%
Mineralys Therapeutics N/A -70.44%-65.51%

Summary

Verona Pharma PLC American Depositary Share beats Mineralys Therapeutics on 8 of the 15 factors compared between the two stocks.

Get Mineralys Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for MLYS and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding MLYS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

MLYS vs. The Competition

MetricMineralys TherapeuticsMED IndustryMedical SectorNASDAQ Exchange
Market Cap$2.79B$3.33B$6.04B$10.42B
Dividend YieldN/A2.31%5.73%4.78%
P/E Ratio-11.8322.4886.3826.98
Price / SalesN/A425.03584.02182.26
Price / CashN/A44.9825.7330.17
Price / Book10.9410.3412.966.65
Net Income-$177.81M-$52.40M$3.31B$276.12M
7 Day Performance10.47%0.61%-0.50%-1.64%
1 Month Performance13.18%13.88%8.66%5.82%
1 Year Performance209.67%27.93%79.84%33.08%

Mineralys Therapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
MLYS
Mineralys Therapeutics
1.7079 of 5 stars
$41.99
-0.4%
$43.50
+3.6%
+210.9%$2.79BN/A-11.8328
VRNA
Verona Pharma PLC American Depositary Share
1.5319 of 5 stars
$106.91
+0.1%
$109.00
+2.0%
N/A$9.20B$42.28M-107.9930Positive News
RVMD
Revolution Medicines
4.054 of 5 stars
$46.58
-0.3%
$74.64
+60.2%
-4.4%$8.73B$11.58M-10.35250
MRUS
Merus
0.9023 of 5 stars
$94.27
0.0%
$93.12
-1.2%
+76.7%$7.13B$56.23M-17.1437
RNA
Avidity Biosciences
1.9455 of 5 stars
$46.18
-1.7%
$68.32
+47.9%
+6.8%$6.86B$10.90M-12.97190
GRFS
Grifols
3.8078 of 5 stars
$9.61
-3.4%
$10.30
+7.2%
+8.5%$6.84B$7.81B8.2123,822Analyst Downgrade
CYTK
Cytokinetics
3.6282 of 5 stars
$60.64
+6.4%
$76.64
+26.4%
+9.4%$6.82B$18.47M-11.89250
RYTM
Rhythm Pharmaceuticals
3.3115 of 5 stars
$97.86
-1.2%
$106.64
+9.0%
+102.4%$6.58B$156.29M-32.51140Positive News
ABVX
Abivax
2.9479 of 5 stars
$86.67
+3.3%
$103.29
+19.2%
+885.0%$6.34BN/A0.0061Analyst Forecast
Gap Up
High Trading Volume
CRSP
CRISPR Therapeutics
1.6655 of 5 stars
$70.19
+3.6%
$71.50
+1.9%
+56.0%$6.16B$35M-12.93460Analyst Forecast
NUVL
Nuvalent
2.8581 of 5 stars
$83.85
-0.4%
$118.89
+41.8%
-15.0%$6.07BN/A-17.1140

Related Companies and Tools


This page (NASDAQ:MLYS) was last updated on 10/13/2025 by MarketBeat.com Staff
From Our Partners